Abstract: PUB386
Complications and Costs of Hyperkalemia in Patients with CKD Stages 3, 4, and 5 Without Dialysis
Session Information
Category: CKD (Non-Dialysis)
- 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials
Authors
- Navarro, Francisco Javier, Hospital General de Culiacan Dr Bernardo J Gastelum, Culiacán, Sin., Mexico
- Moreno Diaz, Samantha Conchita, Hospital General de Culiacan Dr Bernardo J Gastelum, Culiacán, Sin., Mexico
- Maza, Miguel, Hospital General de Culiacan Dr Bernardo J Gastelum, Culiacán, Sin., Mexico
Background
Hyperkalemia is a complication that can negatively affect morbidity and mortality. This study aims to describe the association of hyperkalemia with complications such as hospitalization, dialysis requirements, mortality, and institutional costs in patients with chronic kidney disease stages 3, 4, and 5 without renal replacement therapy.
Methods
An ambispective, observational, analytical, and cross-sectional cohort study was carried out. 76 patients over 18 years of age who were admitted to the hospital with a diagnosis of chronic kidney disease (CKD) in stages 3-5 without renal replacement therapy with a diagnosis of hyperkalemia (serum potassium> 5.3 mmol / l) were included. The temporality was from May 2023 to June 31, 2024. The sampling type was non-probabilistic for convenience. Statistical analysis used: Stata version 13.1 statistical package. Ethical aspects: Compliance with the General Health Law regarding research.
Results
Hyperkalemia severity was identified as a significant predictor of mortality (OR 1.18, 95% CI 1.05-1.33, p=0.006) and hospitalization (OR 1.0004, 95% CI 1.11-1.44, p=0.0004). A significant association was observed between hyperkalemia level and dialysis requirement (p<0.001) according to the Chi-Square test. Institutional costs per patient to treat an episode of hyperkalemia with hemodialysis were five times higher than with potassium exchange resins ($1493 USD vs $270 USD).
Conclusion
These findings demonstrate the importance of using new drugs to treat hyperkalemia, not only to improve clinical outcomes but also to reduce associated healthcare costs.